tbuckley/cabot-search huggingface dataset:
Abstract 228: Short-term Cyclosporine Therapy Increases Ischemia-induced Endothelial Progenitor Cell Mobilization Through Manipulation Of The CD26 System
Authors: Chao Hung Wang, Wen-Jin Cherng, I-Chang Hsieh, Ning-I Yang, Chi-Hsiao Yeh
Journal: Circulation (2007)

Cyclosporine A (CsA), an immunosuppressant, has remarkably improved the short-term success rate of transplantation. The CD26/dipeptidylpeptidase IV (DPP IV) system plays a critical role in mobilizing endothelial progenitor cells (EPCs) from bone marrow. This study investigated whether CsA manipulates CD26/DPP IV activity and increases EPC mobilization. C57 BL/6 mice were divided into control and CsA-treated groups. Circulating EPCs were enumerated before and after hindlimb ischemia was induced. Levels of stroma-derived factor-1α (SDF-1α), stem cell factor (SCF), vascular endothelial grow factor (VEGF), and granulocyte-colony stimulating factor (G-CSF) were measured in the blood. Compared to the controls, CsA treatment significantly increased the serum levels of SDF-1α and SCF (p &lt; 0.001), but not of VEGF or G-CSF after ischemic stress. The CsA group displayed a significant increase in the number of circulating EPCs (with a 7-fold increase in sca-1 + KDR + cells and a 1.5-fold increase in c-kit + CD31 + cells versus the controls at 18 h after ischemia was induced, both p &lt; 0.05). In vivo , CsA also caused 2- and 5-fold increases in the numbers of bone marrow-derived EPCs incorporated into the Matrigel and ischemic limbs, respectively (p &lt; 0.05). In the peripheral blood, CsA significantly decreased CD26 + cell numbers (p &lt; 0.001) and attenuated the plasma CD26/DPP IV activity (p &lt; 0.001). CsA did not alter the acitivty of MMP-2 or MMP-9 in vitro or in vivo . Compared to the controls, short-term CsA treatment significantly improved the perfusion of ischemic limbs and decreased the spontaneous digital amputation rate. In conclusions, this study demonstrated that CsA manipulates the mobilization of bone marrow-derived EPCs into the circulation via the CD26/DPP IV system. Short-term CsA treatment has beneficial effects on angiogensis of ischemic tissues.
Circle fully commits to collaborating with NHS on service transformation
Authors: Paul Manning
Journal: BMJ (2015)

Iacobucci’s article noted that Circle has provided a good dermatology service in Nottingham, but it missed three crucial facts.1

Firstly, dermatologists employed by Nottingham University Hospitals (NUH) have been working for Circle since 2008 and were required to transfer employment to us only in 2013, thanks to a change in national law.

Secondly, the independent review noted that dermatology …
Association Between IVUS Findings and Adverse Outcomes in Patients With Coronary Artery Disease
Authors: Patrick A. Calvert, Daniel R. Obaid, Michael O'Sullivan, Leonard M. Shapiro, Duncan McNab, Cameron G. Densem, Peter M. Schofield, Denise Braganza, Sarah C. Clarke, Kausik K. Ray, Nick E.J. West, Martin R. Bennett
Journal: JACC. Cardiovascular imaging (2011)
The Agar Cell Culture Precipitation Test: Its Application to the Study of Vaccinia Virus, Adenoviruses and Herpes Simplex Virus
Authors: L J MATA
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term effectiveness of transcatheter coil embolotherapy for pulmonary arteriovenous malformation evaluated by 4D dynamic contrast-enhanced 320-slice CT
Authors: Toshihiko Sugiura, Yasunori Kasahara, Takashi Higashide, Hajime Kasai, Norituki Yanagawa, Seiichiro Sakao, Nobuhiro Tanabe, Kouichiro Tatsumi
Journal: European Respiratory Journal (2013)

Purpose: The aim of this study was to retrospectively evaluate the long-term results of transcatheter coil embolotherapy for pulmonary arteriovenous malformation (PAVM) using helical computed tomography (CT) and 4D dynamic contrast-enhanced CT.

Materials and Methods: Twenty-four patients (52±15 yrs, 3 male) underwent follow-up helical chest CT and 4D dynamic contrast-enhanced 320-slice CT (Aquilion ONE, Toshiba Medical) 1-17 years after successful embolotherapy for 29 PAVMs. We estimated the rate of shrinkage of the longest diameter of the aneurysmal sac and the diameter of residual feeding artery with c ontrast-enhanced helical CT. We also evaluated the presence of coil recanalization of PAVM using 4D dynamic contrast-enhanced 320-slice CT.

Results: Twenty-four (83%) of 29 PAVMs had > 30% reduction in the size of the aneurysmal sac or had a residual feeding artery that was < 3 mm based on helical CT. However 10 (42%) of these 24 PAVMs showed recanalization on 4D CT. All 5 PAVMs, which had < 30% reduction in sac size on helical CT, showed recanalization on 4D CT. On the other hand, seven (29%) of 29 PAVMs that had disappearance of the aneurysmal sac showed successful treatment on 4D CT. Finally fifteen (52%) of 29 PAVMs showed recanalization on 4D CT.

Conclusion: Long-term 4D CT follow-up of successfully-treated PAVMs revealed successful embolotherapy of 48% of PAVMs, whereas helical CT revealed successful embolotherapy of 83% of PAVMs. Especially, the marked reduction of the sac size may not reflect long-term successful treatment.
May perpetuate variation in prescribing unrelated to patients' need
Authors: S. J Roberts
Journal: BMJ (1995)

To validate the index the authors correlate it with the level of prescribing of certain drugs, hormone replacement therapy, and tamoxifen, which they regard as indicators of the social class composition of the practice population.This procedure involves unsupported assumptions, particularly in relation to hormone replacement therapy.An underlying problem with the authors' use of PACT data is the implicit assumption that prescribing is a standardised procedure in which general practitioners diagnose and treat disease systematically.The literature does not support this assumption; indeed, it shows great variation among doctors, much of which can be explained only by personal idiosyncrasy.2It seems dangerous to base an objective measure of deprivation on such subjective behaviour.Although the correlation between exempted precriptions and deprivation at health authority level is high, the measure proposed by Lloyd and colleagues is intended for practice based research rather than epidemiological research on larger populations.For example, the authors suggest that it would be useful in researching topics such as prescribing.Given that PACT data are Britain's main source of prescribing data and also provide the data for the authors' deprivation index, however, this suggestion seems tautologous.Further efforts are needed to develop a reliable and valid measure of deprivation at the practice level.
LSC 2013 abstract - Hypoxia-inducible factor 1 alpha polymorphisms in relation to pulmonary involvement in systemic sclerosis
Authors: Harpreet Lota, Carmel Stock, Hiroe Sato, Carmen Fonseca, Athol Wells, Christopher Denton, David Abraham, Gisela Lindahl, Elisabetta Renzoni
Journal: European Respiratory Journal (2013)

Introduction:  Transcription factor hypoxia-inducible factor 1 (HIF1) upregulates the expression of angiogenic genes including vascular endothelial growth factor. Systemic sclerosis (SSc) is a multisystem disease characterised by organ fibrosis and widespread vasculopathy. We assessed the association of two transcriptionally active, single nucleotide polymorphisms (SNPs) of the hypoxia-inducible factor 1 alpha gene (HIF1A) in SSc.   Methods:  Using a case-control study design, HIF1A SNPs (rs11549465 C/T, rs12434438 A/G) were genotyped in SSc patients (n=426) and UK controls from the Wellcome Trust Case-Control Consortium (n=5564 and 5659). The SSc cohort was subdivided according to the presence or absence of pulmonary fibrosis (PF) (n=227 v. 199), pulmonary hypertension (PH) on echocardiography (n=17 v. 129) and autoantibody subsets; anti-topoisomerase I antibodies (n=108) and anti-centromere antibodies (n=105).   Results:  Genotype distribution in all groups conformed to Hardy-Weinberg equilibrium. There were no significant differences in genotype or allele frequencies between SSc and controls (SSc: CC:82.1%, CT:16.7%, TT:1.2% v. controls: CC:81.3%, CT:17.8%, TT:0.9% and SSc: AA:63.9%, AG:32.6%, GG:3.5% v. controls: AA:63.4%, AG:32.5%, GG:4.1%). On subgroup analysis, no significant differences were observed according to PF, autoantibodies, or in the group with available echocardiography (n=146), according to PH.   Conclusion:  An association was not detected between HIF1A SNPs and SSc. Due to limited power in the PH subgroup, an association with pulmonary vascular involvement cannot be excluded and requires further evaluation and longitudinal analysis.
Double J Stents in the Treatment of Gynaecological Injury to the Ureter
Authors: W H Turner, D W Cranston, A H Davies, G J Fellows, J C Smith
Journal: Journal of the Royal Society of Medicine (1990)

Ureteric injury is a recognized complication of hysterectomy and may present with obstruction or fistula. Between 1987 and 1989 in Oxford nine patients with 10 injured ureters underwent attempted retrograde placement of double J stents. Three patients had successful outcomes and one patient with bilateral ureteric obstruction required reimplantation of the right ureter after successful stenting of the left ureter. One patient required removal of a stent due to irritation but her fistula eventually closed. In three patients placement was unsuccessful and in one patient injury to the bladder base prevented the ureteric orifices from being seen and hence stenting was not possible. Thus five of these 10 injured ureters were managed successfully with double J stents. We advocate the initial use of double J stents in gynaecological ureteric injury. This approach is simple and may cure the fistula. If it is unsuccessful, subsequent reimplantation is not hindered.
Autologous plasmin enzyme in the surgical management of diabetic retinopathy4 4Michael T. Trese, MD, George A. Williams, MD, and Michael K. Hartzer, PhD, have a proprietary interest in the use of autologous plasmin enzyme in intraocular surgery.
Authors: Jonathan G Williams, Michael T Trese, George A Williams, Michael K Hartzer
Journal: Ophthalmology (2001)
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
Authors: M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, C. Trask, E. Bessell, C. K. Connolly, J. Tobias, R. L. Souhami
Journal: Journal of Clinical Oncology (1999)

PURPOSE: Chemotherapy for non–small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease. PATIENTS AND METHODS: Ambulatory patients with NSCLC, aged 75 years or younger, with localized disease, were randomized in MIC1 to receive up to four cycles of chemotherapy (CT: mitomycin 6 mg/m 2 , ifosfamide 3 g/m 2 , and cisplatin 50 mg/m 2 ) every 21 days, followed by radical radiotherapy (CT + RT) or radiotherapy (RT) alone. Extensive-stage patients were randomized in MIC2 to identical chemotherapy plus palliative care (CT + PC) or palliative care (PC) alone. Short-term change in quality of life (QOL) was assessed in a subgroup of patients. Data from the two trials were combined to allow multivariate and stratified survival analyses. RESULTS: Seven hundred ninety-seven eligible patients were randomized, 446 in MIC1 and 351 in MIC2. MIC CT improved survival in both trials (significantly in MIC2). The median survival time in MIC1 was 11.7 months (CT + RT) versus 9.7 months (RT alone) (P = .14); whereas in MIC2, median survival time was 6.7 months (CT + PC) compared with 4.8 months (PC alone) (P = .03). QOL, assessed in 134 patients from start of trial to week 6, showed improvement with chemotherapy and deterioration with standard treatment. In the combined analysis of 797 randomized patients, the positive effect of MIC on survival was significant overall (P = .01) and after adjusting for prognostic factors (P = .01). CONCLUSION: MIC chemotherapy prolongs survival in unresectable NSCLC without compromising QOL.
Long lasting CEA specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and GM-CSF. The antibody response correlated significantly to survival
Authors: G. J. Ullenhag, J.-E. Frödin, M. Jeddi-Tehrani, K. Strigård, E. Eriksson, A. Samanci, B. Nilsson, E. D. Rossmann, S. Mosolits, H. Mellstedt
Journal: Journal of Clinical Oncology (2004)

2516 Background: Colorectal carcinoma cells express the antigen CEA. Vaccination trials have indicated that CEA might be a suitable target structure. Methods: Twenty-four CRC patients without macroscopic disease were immunized 7 times with recombinant (r)CEA over a 12 months time period. Half of the patients received the adjuvant cytokine GM-CSF (80μg/day for 4 consecutive days) at each immunization. rCEA was given at 4 different dose levels. The patients were followed immunologically for 36 months and clinically for 76 months. The T cell response was evaluated by a 3H-thymidine incorporation assay and the IgG response was determined by ELISA. Results: Mild local side effects were common. No autoimmune reactions were noted. Twelve out of 12 patients (100%) in the GM-CSF group developed a CEA specific proliferative T cell as well as an IgG response. The corresponding figures in the CEA alone group were 9/12 (75%) and 8/12 (66%) respectively. GM-CSF significantly augmented the amplitude of the T cell response and the IgG titers. No dose-response relationship was noted. The T cell as well as antibody response at 12 months remained 24 months after the last vaccination. Anti-CEA IgG titers correlated significantly to survival (p<0.05) while standard prognostic factors had no impact on survival. Conclusions: Vaccination with rCEA and GM-CSF seems to be a non-toxic regimen inducing strong and long lasting antigen-specific IgG and T cell responses. Anti-CEA IgG titers correlated significantly to survival. This vaccination approach warrants extended trials. No significant financial relationships to disclose.
MEDITERRANEAN TARGET-OVAL CELL SYNDROME IN AN ADULT CHINESE MALE: REPORT OF A CASE
Authors: I. J. Greenblatt, T. D. Cohn, H. L. Deutsch
Journal: Annals of Internal Medicine (1946)

Case Reports1 February 1946MEDITERRANEAN TARGET-OVAL CELL SYNDROME IN AN ADULT CHINESE MALE: REPORT OF A CASEI. J. GREENBLATT, T. D. COHN, H. L. DEUTSCHI. J. GREENBLATTSearch for more papers by this author, T. D. COHNSearch for more papers by this author, H. L. DEUTSCHSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-24-2-259 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn an extensive report on Mediterranean target-oval cell syndrome, Dameshek1proposed the following criteria for its recognition: (a) "The racial factor, (b) a reduction in hemoglobin concentration in association with a low color index, (c) refractoriness to iron therapy, (d) the presence of increased numbers of target cells and reticulocytes, usually in association with oval and stippled red blood corpuscles, (e) the presence of increased hypotonic resistance of the erythrocytes and (f) the absence of such conditions as hepatic disease, steatorrhea, bleeding or lead poisoning." He suggested a probable relationship between this syndrome and Cooley's anemia. It is well known...Bibliography1. DAMESHEK W: Familial Mediterranean target oval cell syndromes, Am. Jr. Med. Sci., 1943, ccv, 643-659. CrossrefGoogle Scholar2. FOSTER LP: Cooley's syndrome (erythroblastic anemia) in a Chinese child, Am. Jr. Dis. Child., 1943, lix, 828-833. Google Scholar3. GREENBLATTGREENBLATT IJAP: In preparation. Google Scholar4. NAJJARKETRON VAKC: Improved thiochrome method for the determination of thiamine in the urine, Jr. Biol. Chem., 1944, clii, 579-584. CrossrefGoogle Scholar5. COOLEYLEE TBOP: Erythroblastic anemia: additional comments, Am. Jr. Dis. Child., 1932, xliii, 705-708. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication November 6, 1944. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOsseous alterations appearing in association with haemopathies of constitutional natureAddendumTHE GENETICS OF HUMAN HAEMOGLOBIN DIFFERENCES: PROBLEMS and PERSPECTIVESUber das Auftreten der Sichelzellkrankheit in GriechenlandHematology 1 February 1946Volume 24, Issue 2Page: 259-261KeywordsAttentionBeta-thalassemiaBlood cellsHemoglobinHemorrhageHepatocytesReticulocytes ePublished: 1 December 2008 Issue Published: 1 February 1946 PDF downloadLoading ...
MEK inhibition is selectively toxic to the genetically defined poor prognosis subset of multiple myeloma overexpressing the c-maf oncogene
Authors: Christina Annunziata, Eric Davis, Lloyd Lam, Elaine Hurt, Arthur Shaffer, Louis Staudt
Journal: Cancer Research (2008)

LB-197   Multiple myeloma is a malignancy of plasma cells characterized by varied oncogenic events. One initiating oncogene is c-maf, a transcription factor that is translocated in 10% of cases, but is transcriptionally upregulated in nearly half of myelomas. The necessity of c-maf in myelomas overexpressing c-maf has been established, but the mechanism of its transcriptional upregulation remains unknown. We discovered that transcriptional upregulation of c-maf occurs more frequently in cases harboring the MMSET/FGFR3 translocation. Both the MAF and the MMSET molecular subgroups have been associated with poor prognosis. We hypothesize that c-maf overexpression is a site for molecular targeting therapeutically. Analysis of c-maf overexpressors indicates c-maf is regulated by MAPK signaling downstream of the MEK-ERK pathway. The c-maf locus contains a region in the promotor and one in the intron that are highly conserved across 17 species, thus suggesting the location of important regulatory elements. MEK inhibition decreased histone acetylation in both regions, and downregulated c-maf mRNA. ERK activation is known to modulate AP-1 transcription factors; we found that the DNA-binding ability of both c-fos and c-jun to the AP-1 consensus sequence was diminished upon MEK inhibition. By chromatin immunoprecipitation, c-fos was bound to the c-maf promoter in myeloma cells and MEK inhibition decreased this interaction. Re-introduction of c-maf cDNA under an exogenous promoter rescued myeloma cell lines from death induced by MEK inhibition. These genetic and functional data demonstrate that the MEK-ERK pathway regulates c-maf transcription. Our findings provide molecular rationale for clinical studies focused at MAPK interruption in this unique poor-prognostic subset of multiple myeloma overexpressing c-maf.
Abstract 5754: Cardiac CT Angiography vs. SPECT Perfusion Imaging for the Evaluation of Patients with Acute Chest Pain
Authors: Ian S Rogers, Jamaluddin Moloo, Claudia U Chae, Ron Blankstein, Fabian Bamberg, Antonio J Pena, Sujith K Seneviratne, Quynh A Truong, John H Nichols, Maros Ferencik, David F Brown, John T Nagurney, Thomas J Brady, Udo Hoffmann
Journal: Circulation (2008)

BACKGROUND: Over 5 million individuals present to EDs with acute chest pain each year, many of which are hospitalized for serial EKGs and cardiac enzymes followed by stress SPECT imaging. A potential alternative to SPECT is cardiac CT, which provides for the immediate and direct evaluation of coronary artery patency. We sought to determine the concordance between these modalities and the ability of CT to exclude ischemia in patients presenting with acute chest pain. METHODS: We enrolled 368 subjects without a history of hemodynamically significant CAD who presented to the ED with acute chest pain yet had negative initial EKGs and cardiac enzymes. All subjects underwent 64-slice cardiac CTA, the results of which were blinded to caregivers, then were admitted for standard care including diagnostic testing, as deemed clinically warranted by the caregivers. CTA exams were scored as being diagnostically positive or negative for significant stenosis (&gt;50% luminal narrowing) or as non-diagnostic. SPECT exams were scored as diagnostically pos or neg for ischemia or scar or as non-diagnostic (e.g., secondary to submaximal workload or artifact). RESULTS: 151 of the 368 subjects (54±11 yrs, 56% men) had an exercise (n=109), adenosine (n=41), or dobutamine (n=1) SPECT exam as part of their clinical care. 115 (76%) of the SPECT exams were read as diagnostic (7 pos for ischemia, 2 pos for scar, and 106 neg), while 36 (24%) were non-diagnostic. In contrast, 135 of the 151 (89%) of the CT exams were read as diagnostic (17 pos, 118 neg), while only 16 (11%) were non-diagnostic (p &lt;0.001). Among the 105 patients that had both diagnostic CT and SPECT exams, there was agreement between the modalities in 97/105 (92%) of patients. With SPECT defined as the standard for detecting ischemia, absence of significant stenosis on a diagnostic CT had a 98% NPV for excluding ischemia. CONCLUSION: Cardiac CT appears to be as feasible as SPECT imaging in patients with acute chest pain but inconclusive initial ED evaluation and may have a lower rate of non-diagnostic exams. Consistent with the known high NPV of CCT, absence of significant stenosis on cardiac CT predicted the absence of SPECT based ischemia in 98% of subjects. Thus, cardiac CT may be sufficient to exclude ischemia in patients with acute chest pain.